Category: Cancer Treatment
Serial entrepreneur Eric Lefkofsky has founded or co-founded more than a dozen companies. The one that’s best known is Groupon. However, Tempus Labs, a company Lefkofsky co-founded in 2015, is now getting international interest for the role it is playing in transforming cancer research, treatment and therapies. The staff at Tempus has created technology that allows for machine reading of data from medical records as well as pathology and medical imaging, improves cancer testing, assists in the sequencing of both the RNA and DNA of tumors and makes processing organoid cultures of patient’s tumor cells easier. Tempus is revolutionizing the access to and use of big data.
The innovative new technology Tempus has devised is recognized as one of the top 10 breakthrough in modern medicine by Dr. Eric Topol. He has added it to the list of brilliant medical advances he publishes on a yearly basis. Dr. Topol’s list also includes groundbreaking scientific innovations like the KardiaBand used in artrial fibrillation diagnosis, the blood pressure watch, two new recently developed glucose sensors, artificial intelligence technology for diagnosing eye disease, the new deep-learning algorithm which diagnoses skin cancer, exciting new gene editing as well as gene therapy technology and the effective new cancer treatment called Chimeric antigen receptor T Immunotheraphy.
Born in Southfield, Michigan, Eric Lefkofsky got a bachelor’s degree from the University of Michigan in 1991 and his juris doctor from the university’s law school in 1993. He then went on to start a long list of companies. They include Brandon Apparel, print procurement company InnerWorkings, Echo Global Logistics, a freight logistics company, advertising technology company MediaBank, Mediaocean, analytics company Uptake, venture capital firm Lightbank and his most lucrative company, Groupon, one of the world’s fastest growing companies.
Eric Lefkofsky is a committed philanthropist. His Lefkofsky Family Foundation supports over 50 organizations involved in improving education, medical care, access to culture and the arts and more for children all over the world. He works with numerous Chicago, social, cultural, business and civic organizations. In 2013, Lefkofsky agreed to give his vast wealth to charity by joining The Giving Pledge.
For details: lefkofskyfoundation.com/about-eric-lefkofsky/
Men who are more than 60 years old and have prostate cancer should have them removed by surgery. This is according to the opinion of Dr. David Samadi, a Urologist at Lenox Hill Hospital. Actually, he is more than a regular doctor at the hospital. He is its Chairman and he is also a board certified urologist. He bases his opinion on the actual experiences of three prominent political figures in the United States, Mitt Romney, Colin Powell, and John Kerry who are all in their mid-60s.
Annoying cold sores and fever blisters are bad enough. But even worse are blindness, birth defects and even cancer which at times have been attributed to a very common form of a virus that up to 90% of Americans have been exposed to – the herpes virus. Herpes simplex virus or HSV is a virus that can appear in various parts of the body, most commonly the genitals or mouth. Once we have the virus inside of us, we can’t get rid of it on our own. It can lie in dormancy inside cells for long periods of time until something triggers it to flare up causing various symptoms. #health #healthtips #prevention
All three have undergone surgery to treat their prostate cancers. Romney has recently announced that he has undergone this type of surgery and came out successfully treated. Dr. Thomas Ahlering performed the successful surgery on Romney. Some have speculated why Romney made this interesting announcement. They believe that he must be thinking of running again for president and tacitly telling the voters that he can because he is in the pink of health.
Colin Power, George Bush II’s Secretary of State, on the other hand, was also operated on and had his prostate gland removed in 2003. The third politician to undergo prostate surgery is John Kerry, President Obama’s State Secretary. It seems Kerry has had no remissions ever since his operation. All three men are in their mid or late 60s. That’s no mere fluke as the statistics will show.
It appears that prostate cancer develops in men who are in their advanced years. The statistics reveal that in 10 cases of the malady, 6 occur in men who are 65 years old and above. It was also indicated in these stats that those who are below 40 years of age have very low risk of contracting this disease since it rarely develops at this earlier stage.
In Samadi’s opinion, surgery is the best way to handle the problem of prostate cancer. He bases his opinion on the experiences of the three political figures mentioned above. All three have successfully licked the problem by undergoing surgery. They have not chosen the other method of dealing with the problem – radiation. Their doctors must have known that it is better to operate than to radiate.
Dr. Samadi was not just expressing his personal opinion about the better results of surgery for prostate cancer compared to the other method of radiation. He bases his belief on his many years of experience as a urologist. At Lenox Hill Hospital, he is also the Chief of Robotic Surgery. He must have used this advanced form of surgery many times to treat his patients suffering from prostate cancer.
For More info: insider.foxnews.com/tag/dr-david-samadi
If you haven’t heard of Dr. Clay Siegall, he is the Founder and CEO of Seattle Genetics, a biotechnology company predicated on the development of targeted therapy drugs. In layman’s terms, these are drugs aimed at delivering a concentration of medication to a specific part of the body, localized cancers being a primary example. Since being founded in 1998, Dr. Siegall and his team at Seattle Genetics have worked diligently towards creating pharmacotherapies aimed at improving mortality rates, in those who have been diagnosed with serious diseases. In fact, in November 2017, Seattle Genetics received FDA approval for one of their antibody drug conjugates, Adcetris. The drug is reportedly used to treat patients diagnosed with Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
According to his Linkedin bio, Dr. Siegall attended George Washinton University, where he earned a Ph.D. in Genetics. Shortly thereafter, he earned a B.S. in Zoology from the University of Maryland. In an interview with inspirey.com, Dr. Siegall delineates the impetus for his interest in medicine, in what could only be described as veritable candor; he describes having to witness a family member undergo a cancer treatment regimen that nearly resulted in their death. It was at this point when the idea of pursuing a career in medicine began to flourish.
Prior to his role as Founder and CEO of Seattle Genetics, Dr. Clay Siegall worked with Bristol-Myers Squibb, where he served as the company’s Senior Research Investigator from 1991 to 1995. In 1995, he became the company’s Principal Scientist, maintaining that role until 1997, before establishing Seattle Genetics in 1998. In addition to his work in cancer research and therapeutic drug development, Dr. Siegall has also served as the Director for Washington Biotechnology and Biomedical Association, as well as non-executive Director for Mirna Therapeutics, Inc.
Collectively, Dr. Clay Siegall has a well over 20-years of industry experience and has written upwards of 67 scientific papers, easily making him one of the foremost experts in the world of cancer research. Dr. Seigall currently sits on the editorial board for three scientific journals and has been the recipient of several awards, including the Pacific Northwest Ernst and Young Entrepreneur of the year, as well as University of Maryland’s Alumnus of the year.